 |
|
|
| |
Real-World Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in HCV:
A Multi -Country Analysis of Post-Marketing Observational Studies
|
| |
| |
Reported by Jules Levin
European Associati on for the Study of the Liver's 54th Annual Internati onal Liver Congress, 10-14 April 2019, Vienna, Austria
Pietro Lampertico1, Markus Peck-Radosavljevic2, Mark Bondin3, Yves Horsmans4, Nasser Semmo5, Sadhana Sonparote3, Zhenzhen Zhang3, Ariel Porcalla3, Ella Veitsman6, Konstanti nos Mimidis7, Robert Flisiak8, Dominique Thabut9
1CRC "AM e A Migliavacca" Center for Liver Diseases, Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; 2Department of Internal Medicine and Gastroenterology, Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria; 3AbbVie Inc., North Chicago, Illinois, United States; 4Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium; 5Department of BioMedical Research, Hepatology, Inselspital, University of Bern, CH-3010 Bern, Switzerland; 6Liver Unit, Rambam Health Care Campus, Haifa, Israel; 7First Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece; 8Department of Infecti ous Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland; 9Paris Sorbonne Universite, AP-HP, Hôpital Pitie Salpêtriere, Service d'Hepatologie, Paris, France
|
| |
|
|
|
|
|
